PETQ · Petiq, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $328.94M | $308.44M | - | $277.02M | $252.01M | $275.69M | - | $210.53M | $252.01M | $275.69M |
| Cost of Revenue | $240.66M | $233.90M | - | $204.41M | $240.67M | $228.21M | - | $158.96M | $190.04M | $218.06M |
| Gross Profit | $88.28M | $74.54M | - | $72.61M | $73.88M | $62.26M | - | $50.77M | $61.97M | $57.63M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $60.08M | $50.21M | - | $55.02M | $55.16M | $43.33M | - | $45.98M | $50.59M | $48.24M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $3.16M | $8.36M | - | $10.85M | $4.16M | $8.46M | - | $3.58M | $3.52M | $8.97M |
| Operating Income | $25.58M | $24.33M | - | $9.36M | $18.72M | $18.93M | - | ($42.48M) | $11.38M | $9.40M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $885.0K | $327.0K | - | $283.0K | $192.0K | $448.0K | - | ($355.0K) | $603.0K | $121.0K |
| Net Income | $15.32M | $14.91M | - | $451.0K | $9.47M | $9.70M | - | ($49.14M) | $4.63M | $3.13M |
| EPS - Basic | $0.52 | $0.51 | - | $0.02 | $0.32 | $0.33 | - | ($1.68) | $0.16 | $0.11 |
| EPS - Diluted | $0.49 | $0.48 | - | $0.02 | $0.32 | $0.32 | - | ($1.68) | $0.16 | $0.11 |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84.13M | $25.37M | $116.37M | $124.61M | $78.44M | $25.41M | $101.27M | $56.72M | $5.40M | $51.10M |
| Accounts Receivable | $214.98M | $191.86M | $142.51M | $151.68M | $193.57M | $203.32M | $118.00M | $125.02M | $168.83M | $179.06M |
| Inventory | $164.97M | $215.38M | $159.31M | $128.13M | $141.65M | $158.09M | $142.60M | $147.05M | $160.06M | $167.71M |
| Accounts Payable | $142.23M | $137.86M | $139.26M | $113.45M | $154.14M | $150.01M | $113.00M | $73.40M | $81.09M | $128.91M |
| Current Assets | $471.05M | $444.92M | $430.83M | $410.66M | $422.44M | $397.15M | $370.11M | $336.18M | $343.63M | $408.02M |
| Total Assets | $894.39M | $875.24M | $868.23M | $857.09M | $883.47M | $867.72M | $818.90M | $791.71M | $855.03M | $924.43M |
| Current Liabilities | $182.68M | $184.00M | $189.53M | $164.64M | $191.70M | $186.19M | $149.49M | $115.91M | $119.17M | $173.41M |
| Long-term Debt | $436.01M | $436.42M | $437.82M | $439.21M | $440.58M | $441.94M | $443.28M | $444.60M | $450.90M | $472.94M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $260.31M | $237.85M | $223.00M | $239.17M | $235.60M | $223.15M | $211.79M | $215.31M | $267.44M | $261.16M |
| Retained Earnings | ($130.37M) | ($145.69M) | ($160.60M) | ($143.12M) | ($143.57M) | ($153.03M) | ($162.73M) | ($155.90M) | ($106.76M) | ($111.39M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($85.14M) | - | - | - | ($43.33M) | - | - | - | ($45.38M) |
| Investing Cash Flow | - | ($822.0K) | - | - | - | ($29.54M) | - | - | - | ($5.68M) |
| Financing Cash Flow | - | ($5.07M) | - | - | - | ($3.09M) | - | - | - | $22.86M |
| CapEx | - | $1.55M | - | - | - | $1.91M | - | - | - | $5.68M |
| Free Cash Flow | - | ($86.69M) | - | - | - | ($45.24M) | - | - | - | ($51.06M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 26.8% | 24.2% | - | 26.2% | 29.3% | 22.6% | - | 24.1% | 24.6% | 20.9% |
| Operating margin | 7.8% | 7.9% | - | 3.4% | 7.4% | 6.9% | - | -20.2% | 4.5% | 3.4% |
| EBITDA margin | 8.7% | 10.6% | - | 7.3% | 9.1% | 9.9% | - | -18.5% | 5.9% | 6.7% |
| Net margin | 4.7% | 4.8% | - | 0.2% | 3.8% | 3.5% | - | -23.3% | 1.8% | 1.1% |
| Free cash flow margin | - | -28.1% | - | - | - | -16.4% | - | - | - | -18.5% |
| FCF / Net income | - | -5.82 | - | - | - | -4.66 | - | - | - | -16.31 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 18.3% | 16.3% | - | 19.9% | 21.9% | 15.7% | - | 21.8% | 20.1% | 17.5% |
| Effective tax rate | 5.5% | 2.1% | - | 38.6% | 2.0% | 4.4% | - | - | 11.5% | 3.7% |
| Return on assets | 1.7% | 1.7% | - | 0.1% | 1.1% | 1.1% | - | -6.2% | 0.5% | 0.3% |
| Return on equity | 5.9% | 6.3% | - | 0.2% | 4.0% | 4.3% | - | -22.8% | 1.7% | 1.2% |
| Return on invested capital | 3.5% | 3.5% | - | 0.8% | 2.7% | 2.7% | - | -5.1% | 1.4% | 1.2% |
| Liquidity | ||||||||||
| Current ratio | 2.58 | 2.42 | 2.27 | 2.49 | 2.20 | 2.13 | 2.48 | 2.90 | 2.88 | 2.35 |
| Quick ratio | 1.68 | 1.25 | 1.43 | 1.72 | 1.46 | 1.28 | 1.52 | 1.63 | 1.54 | 1.39 |
| Cash ratio | 0.46 | 0.14 | 0.61 | 0.76 | 0.41 | 0.14 | 0.68 | 0.49 | 0.05 | 0.29 |
| Leverage | ||||||||||
| Debt / Equity | 1.67 | 1.83 | 1.96 | 1.84 | 1.87 | 1.98 | 2.09 | 2.06 | 1.69 | 1.81 |
| Debt / Assets | 0.49 | 0.50 | 0.50 | 0.51 | 0.50 | 0.51 | 0.54 | 0.56 | 0.53 | 0.51 |
| Debt / EBITDA | 15.17 | 13.35 | - | 21.74 | 19.25 | 16.13 | - | - | 30.27 | 25.75 |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.44 | 3.68 | 3.89 | 3.58 | 3.75 | 3.89 | 3.87 | 3.68 | 3.20 | 3.54 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.37 | 0.35 | - | 0.32 | 0.29 | 0.32 | - | 0.27 | 0.29 | 0.30 |
| Inventory turnover | 1.46 | 1.09 | - | 1.60 | 1.70 | 1.44 | - | 1.08 | 1.19 | 1.30 |
| Days sales outstanding | 239d | 227d | - | 200d | 280d | 269d | - | 217d | 245d | 237d |
| Days inventory outstanding | 250d | 336d | - | 229d | 215d | 253d | - | 338d | 307d | 281d |
| Days payable outstanding | 216d | 215d | - | 203d | 234d | 240d | - | 169d | 156d | 216d |
| Cash conversion cycle | 273d | 348d | - | 226d | 261d | 282d | - | 386d | 396d | 302d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 30.5% | 11.9% | - | 31.6% | 0.0% | 0.0% | - | 0.0% | -7.0% | 8.4% |
| Revenue CAGR (3y) | 6.7% | 6.6% | - | 19.6% | -1.9% | 13.9% | - | 4.2% | 4.5% | 22.9% |
| Revenue CAGR (5y) | 8.3% | 15.8% | - | 16.1% | 23.7% | 19.1% | - | 28.3% | - | - |
| Gross profit growth (YoY) | 19.5% | 19.7% | - | 43.0% | 19.2% | 8.0% | - | 20.7% | 3.9% | 20.6% |
| Operating income growth (YoY) | 36.7% | 28.5% | - | - | 64.5% | 101.5% | - | -1235.8% | -31.0% | 31.9% |
| Net income growth (YoY) | 61.8% | 53.7% | - | - | 104.4% | 209.8% | - | -521.8% | 15.1% | 54.0% |
| EPS growth (YoY) | 53.1% | 50.0% | - | - | 100.0% | 190.9% | - | -522.2% | 14.3% | 37.5% |
| EPS CAGR (3y) | 51.8% | 81.7% | - | - | - | - | - | - | -2.0% | 16.3% |
| EPS CAGR (5y) | 23.6% | 47.0% | - | -31.2% | 14.9% | - | - | - | - | - |
| FCF growth (YoY) | - | -91.6% | - | - | - | 11.4% | - | - | - | 22.3% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 10.5% | 6.6% | 5.3% | 11.1% | -11.9% | -14.6% | -17.0% | -18.2% | -0.8% | 1.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Business segments
$1.10B totalProducts$968.15M · 87.9%
Services$133.81M · 12.1%
Product / service
$1.10B totalProduct$968.15M · 87.9%
Service$133.81M · 12.1%
Geographic
$968.15M totalUS$960.35M · 99.2%
Non Us$7.80M · 0.8%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing PetIQ against the 5 most active filers in the same SIC group.